Brief: Onco Therapy Science to start Phase I clinical study for breast cancer patients in U.S.

OncoTherapy Science

20/09/2016 02:28

Sept 20 (Reuters) - Onco Therapy Science Inc   4564.T :   
     
     
    * Says the co will conduct Phase I clinical study of OTS167, 
a MELK specific inhibitor, for breast cancer patients following 
the acceptance of the protocol by the U.S. Food and Drug 
Administration 
     
     
    Source text in Japanese:https://goo.gl/fyJhXT 
    Further company coverage: 4564.T  
 
 (Beijing Headline News) 
 ((Beijing.HeadlineNews@thomsonreuters.com; +86 10 62674724; 
Reuters Messaging: jun.cao.reuters.com@reuters.net))